Wed, Sep 17, 2014, 3:43 PM EDT - U.S. Markets close in 17 mins.

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • biotechinvest1077 biotechinvest1077 May 8, 2013 10:56 PM Flag

    The Party is Over

    Folks, ISIS has had a great run but the chart says it time to sell. It was run up for the secondary offering and now the air will come out. Don't look back till after tax loss selling has run its course.

    Take a look at ARWR.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • That's what they said about Biogen at 120.

      Sentiment: Strong Buy

    • There isn't any tax loss selling when you are up over 100% on the year. ARWR will be a dog for at least three years. t

      • 1 Reply to jetmanbash
      • Hi Jet,

        I hope you are well. Congrats on being right about ISIS when the stock was in the doldrums and congrats on sticking with it. I made some decent money with ISIS but sold substantially lower than current levels.

        I do realize that there won't be any tax loss selling if ISIS remains at or near current levels. My post anticipates/assumes ISIS will sell off and this will result in tax loss selling by year end. Time will tell whether I am right or wrong.

        Since I have always appreciated your knowledge and value your opinion, please explain why you think ARWR will be a dog for 3 years. I like the risk reward of ARWR very much and think buying at the current level will prove to be extremely profitable in the near term. I'd very much like to hear why you are so negative on ARWR.

        TIA

    • ISIS is a NEWS/PIPELINE driven story so when they issue positive CRP or APO3 or STAT3 or TTLR or ect .....

      the stock is going up. The stock will be in the mid/high $20's by year-end, and just maybe it breaks $30 on a volume push. ISIS is signalling to these over subscribed investors a positive pipeline news front.

      I HOPE WE GO INTO THE $18 AS ITS GOING TO BE ONE OF THE LAST CHEAP BUYING OPS

      THIS SHELF OFFERING IS GOING TO QUALITY BUY & HOLD FUND TYPE CLIENTs. GS will at some point in the near future put ISIS on their top tier small cap biotech buy list. If you don't think so!!! Think Again.

      boxcarwhillie

      • 2 Replies to boxcarlong
      • I stand by $22-$24 Thought 31 was to high for the end of 2013 unless something amazingly unexpected happened. This sale of common stock is 100% not the unexpected surprise one would hope for, but they'll get it, and I believe the stock will climb above $20 after the dust settles and some good news comes out.

        Being able to negotiate a higher percentage share of the drugs they develop should be a decent LONG term strategy. It just sucks for right now. Selling that 20% was luck. Not buying puts afterward was stupid. Being able to buy on a pull back like this sounds like a good idea.

        The market has a tenancy to over react to ISIS.

        Actually just sold some JUNE 19 and bought some June 18 Puts to make a couple bucks. While I'm willing to bet that the stock stays in the 18's I wouldn't be surprised to see it drop to the 15's before it started to climb again.

        LOTS of buy and holders, including institutions.

      • $18 s ????? You are there sucker.

 
ISIS
41.175+1.675(+4.24%)3:43 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.